|
Study on Multidrug-Resistant Pseudomonas aeruginosa
Researchers reported that high-dose inhaled nitric oxide reduced drug-resistant bacteria in a large-animal ICU model and was found safe in early human testing. The findings relate to treatment of drug-resistant pneumonia.
Pneumonia & Nitric Oxide Therapy
| Dimension | Key Details |
|---|---|
| Definition of Pneumonia | Infection of the lungs causing inflammation of alveoli with fluid or pus accumulation |
| Types | Community-acquired, hospital or ventilator-associated and aspiration pneumonia |
| Bacterial Causes | Includes Streptococcus pneumoniae, Haemophilus influenzae, Legionella pneumophila and Mycoplasma pneumoniae |
| Viral and Fungal Causes | Includes Influenza, COVID-19, respiratory syncytial virus, human metapneumovirus and Pneumocystis jirovecii |
| Symptoms | Fever, cough with mucus, breathlessness, chest pain, fatigue and bluish lips or nails |
| Risk Factors | Chronic diseases, weak immunity, smoking, pollutant exposure, indoor biomass fuel use and crowded living conditions |
| Diagnosis | Clinical examination, imaging, blood tests, sputum test and pulse oximetry |
| Standard Treatment | Antibiotics or other drugs, oxygen therapy, hospitalisation and supportive care |
| Drug-Resistant Agent | Pseudomonas aeruginosa causing about one in five hospital pneumonias |
| Nitric Oxide Nature | Naturally produced in the human body and used medically at low doses to widen blood vessels |
| High-Dose Findings | Inhaled nitric oxide at 300 ppm reduced lung bacterial counts by 99% in ventilated pigs |
| Human Testing | Phase-1 study in healthy volunteers showed no serious adverse effects |
| Limitations | Potential elevation of methemoglobin, lung injury risk and need for specialised equipment and monitoring |